Added to YB: 2025-10-08
Pitch date: 2025-10-05
ABBV [neutral]
AbbVie Inc.
-2.93%
current return
Author Info
Disruptive Analytics has 30+ years of experience as a retail investor and is now fully engaged in managing their own money. Sign up for the newsletter.
Company Info
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.
Market Cap
$394.3B
Pitch Price
$230.05
Price Target
N/A
Dividend
3.10%
EV/EBITDA
15.32
P/E
168.95
EV/Sales
7.67
Sector
Biotechnology
Category
growth
Targeted Chemotherapy - AbbVie Inc.
ABBV (overview - fairly valued): Leads w/ 2 diverse chemo ADCs - Elahere (ovarian cancer, $159M Q2 rev +24.2% QoQ, est $750M 2025 sales growing to $6B by 2034) & Emrelis (NSCLC, $0.5-1B sales by 2029). Oncology only $1.7B of $15B+ total rev but key growth driver. +20% returns, no longer undervalued.
Read full article (2 min)